tb intensive · 11/15/2011 1 tb intensive san antonio, texas november 29-december 2 december 2,...
TRANSCRIPT
11/15/2011
1
TB IntensiveSan Antonio, Texas
November 29 December 2 2011November 29-December 2, 2011
Pediatric TBAndrea Cruz, MD, MPH
December 2, 2011
Andrea Cruz, MD, MPH has thefollowing disclosures to make:
• No conflict of interests• No conflict of interests
• No relevant financial relationships with any commercial companies pertaining to this educational activityto this educational activity
11/15/2011
2
An Introduction to Childhood Tuberculosis
Andrea T Cruz MD/MPH
Pediatrics
Andrea T. Cruz, MD/MPH
Assistant Professor of Pediatrics
Sections of Emergency Medicine & Infectious Disease
Objectives
•To understand the definitions we use for childhood TB
•To know the common clinical and radiographic manifestations of childhood TB
•To understand the utility and limitations of available TB diagnostics
•To map out a plan of care (and know how to get
Page 3
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
To map out a plan of care (and know how to get help) for children with TB exposure, infection, and disease
11/15/2011
3
Population Distribution
Page 4
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics www.worldmapper.org
World map showing territory size as a proportion of the world’s population
Geography of TB
Page 5
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics www.worldmapper.org
World map showing territory size as a proportion of the world’s TB cases found there
11/15/2011
4
Famous People with TB
•JFK*
•Eleanor Roosevelt
•Bronte (x3)
•Fyodor Dostoyevsky
•Nelson Mandela
•Simon Bolivar
•King Tut
•Henry David Thoreau
•Ralph Waldo Emerson
•Franz Kafka
•John Keats
•Edgar Allan Poe*: possibly
Page 6
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
•Edgar Allan Poe
•R.L. Stevenson
•Frederic Chopin
www.dhss.delaware.gov/dph/dpc/tbfamouspeople
: possibly
National Epidemiology: 2010 Data
Page 7
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
MMWR 2011;60:333
11/15/2011
5
Texas Epidemiology
Harris County: •2005 – 379 cases•2005 – 379 cases•2006 – 402 cases •2007 – 394 cases•2008 – 398 cases•2009 – 396 cases•2010 – 341 cases
Page 8
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
http://www.dshs.state.tx.us/idcu/disease/tb/statistics
•4-5 times the average national incidence
Definitions we use for TB
Category Age Exam PPD/IGRA
CXR Contagious Treatment
Exposure < 5 ‐ ‐ ‐ Never 1 drug, usually for 2‐3 months (given by health department)
Infection All ‐ + ‐ Never Usually 1 drug, given 6‐9 months (given by family or health department)
Disease All ‐/+ +/‐ +/‐ Rarely Multiple drugs (3‐4), given 6‐12 months (always given by health
Page 9
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
months (always given by health department)
No patient with nontuberculous mycobacteria is contagious
11/15/2011
6
Childhood TB Disease Sites
Site* % of cases Median Age (years)
Pulmonary 77.5 6
Lymphatic 13.3 5
Pleural 3.1 16
Meningeal 1.9 2
Bone/joint 1.2 8
Page 10
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Miliary 0.9 1
GU 0.8 16
Peritoneal 0.3 13*: United States (almost all are normal hosts)
Risk of Progression from TB Infection to Disease by Age
Page 11
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Peds in Review 2010;31:13
11/15/2011
7
Signs and Symptoms of Pulmonary TB
Page 12
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Peds in Review 2010;31:13
Available Diagnostic Tools
Tool Older
Generation
Newer
Generation
R di h CXR CT*Radiography CXR CT*
Immune response Skin test Interferon assay
Specimen collection
Gastric aspirates Induced sputa
Page 13
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
PCR Sputum Other body fluids
*CT is not the standard of care for the diagnosis of pulmonary TB, and is not necessary for the vast majority of children with pulmonary TB disease
11/15/2011
8
One difference between adults & kidsModality Adult
Studies*Pedi
Studies*∆ Ratio adult to
pediYear of 1st
publication
Culture: Solid
400 38 ‐362 11x 1967
Culture: Liquid
248 13 ‐235 19x 1966
MODS 37 7 ‐30 5x 2000
PPD/TST 6399 2031 ‐4368 3x 1907
IGRA 344 87 ‐257 4x 1999
Page 14
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Xpert 7 1 ‐6 7x 2010
PCR, all 1831 187 ‐1644 10x 1990
*: PubMed Queries as of 7/27/11
CXR Findings in Pediatric TB
•Hilar or mediastinal adenopathy
•Segmental/lobar infiltrates
•Calcifications (seen in 75-80% of children with pulmonary TB)
•Miliary disease
•Pleural effusions
Page 15
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
15% of patients with TB disease will have normal CXRs
11/15/2011
9
Intrathoracic Lymphadenopathy
Page 16
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
N.O. 2008
Lobar Infiltrates
9mo M presents to TB clinic with 23mm PPD done after grandfather diagnosed with smear‐positive pulmonary TB. Baby is asymptomatic, normal vital signs, growing well.
Page 17
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
D.T. 2011
o a ta s g s, g o g eAdmitted for LP (normal), gastric aspirates (smear‐negative), started on multidrug therapy for TB disease
11/15/2011
10
Collapse/Consolidation Pattern
Page 18
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Lymph node collapses a bronchus, leading to distal atelectasis M.A. 2009
Calcifications
Page 19
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Usually indicates disease present for 2‐6 months W.C. 2005
11/15/2011
11
Cavitary Lesions
Page 20
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
W.C. 2005
Cavitary Lesions
Page 21
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Uncommon in children, but if see cavities, treat the child as contagious and take appropriate infection control precautions M.N. 2007
11/15/2011
12
Cavitary Lesion
•16yo M with very poorly controlled IDDM
•2 months of productive cough, weight loss
• Smear-positive TB
Page 22
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Int J Tuberc Lung Dis 2011;15:179
* DM is single most common predisposing medical condition in TX adults with TB disease
J.A. 2010
Miliary Disease
Page 23
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
P.K. 2008
11/15/2011
13
2003: 17yo WM with Crohn’s, on anti‐TNFα therapy, negative baseline TST, developed miliary TB after 2 months
Page 24
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
C.A. 2004
Miliary TB with Tension Pneumothorax
Page 25
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
D.M. 2008
11/15/2011
14
Miliary TB in Spleen, Liver
Page 26
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
D.M. 2008
Pleural Effusions
Page 27
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Often, children are very well‐appearing (vs. Staph empyemas) J.G. 2007
11/15/2011
15
Tuberculomas
Page 28
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
At initiation of therapyAfter 2 months of therapy
W.C. 2005
Tuberculous Pericarditis
Page 29
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
11/15/2011
16
Lymphadenopathy + Scrofuloderma
Page 30
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics Paed Resp Rev 2007;8:107
Comparison: Nontuberculous Mycobacterial lymphadenopathy
Page 31
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
T.O. 2010A.J. 2009
11/15/2011
17
Cutaneous TB: Lupus vulgaris
Page 32
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
M.R. 2010
Skeletal TB
Page 33
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
11/15/2011
18
Pott’s Disease
J.M. 1/2011. 3yo F with 1yr of worsening ‘hunchback’ (gibbous deformity). T5 destruction. Culture: M. bovis
Page 34
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Clin Infect Dis 2005;41:515
Immune System Recognition
•Tuberculin skin tests (PPD)
•Interferon gamma release assays (IGRA)
Page 35
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
11/15/2011
19
PPD Placement
No controls
Need to see a wheal raised
No controls
Page 36
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Positive PPDs
Page 37
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Generally, skin test conversion occurs within 2 months of contact
Measure only induration, and record millimeters of induration (never record “+” or “‐”)
Any induration seen only in the first 24 hours should be ignored
Induration after 72 hours counts; blistering also counts
11/15/2011
20
What is a Positive PPD?
•≥ 5 mm:‐HIV+ or other immunocompromise‐Contact with suspected source caseSuspected TB disease‐Suspected TB disease
•≥ 10 mm: ‐Immigrants from high-prevalence areas‐Children under 4 years of age‐Children exposed to adults in high-risk categories‐Other immunocompromising conditions
Page 38
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
•≥ 15 mm: ‐anyone, even without risk factors
2009 Red Book
Who does AAP Recommend Skin Testing? •Universal skin testing is NOT recommended•Initial PPD should be done before initiation of immunosuppressive therapy (including prolongedimmunosuppressive therapy (including prolonged steroid usage, TNF-α antagonists)
•Annual PPDs: HIV+ or incarcerated•Q2-3yr testing should be considered: high-risk•Immediate PPD should be placed:
‐As part of contact investigation
Page 39
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
p g‐CXR or clinical findings consistent with TB‐Children emigrating from endemic countries‐Children with travel history to or contact with persons from endemic countries
2009 Red Book
11/15/2011
21
Validated Questions to Determine LTBI Risk•Has a relative or contact had TB disease?
•Has a family member had a positive TB skin test?
•Was the child born in a high-risk country?
•Has your child traveled to a high-risk country for > 1 week?
•Should consider screening for risk factors at the
Page 40
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Should consider screening for risk factors at the initial visit and every 6 months thereafter in first 2 years of life
Pediatrics 2001;107:e54; Red Book 2009
PPD Limitations
False positives:
•Exposure to mycobacteria other than TB
•Inter-observer variability
•Sliding scale for what is considered positive can beother than TB
•BCG vaccine
False negatives:
•Corticosteroid usage
Other immunocompromise
considered positive can be confusing
•Until very recently, lack of any confirmatory tests
Page 41
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
•Other immunocompromise
•Viral suppression: measles, mumps, influenza
11/15/2011
22
PPD: Myths surrounding BCG
•Myth: PPDs will be positive in all patients who received BCG vaccination
R lit 50% f i f t i i BCG d t t t ki‐Reality: 50% of infants receiving BCG do not react to skin tests, and most of the rest stop reacting within 5 years
•Myth: PPDs can be neither placed nor interpreted in BCG recipients
‐Reality: different cut-off points for the skin test are not
Page 42
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
y precommended based upon a child’s BCG status
So, What Are Alternatives?
•Since 2005: 2 commercially available blood tests, interferon gamma release assays (IGRA) that offer more specificity than the skin test
Page 43
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
11/15/2011
23
IGRAs•Interferon-γ release assays (IGRAs) detect host response to Mycobacterium tuberculosis-specific antigens
•Two main tests currently FDA-approved:
‐T-SPOT.TB
Q tiFERON G ld I T b
Page 44
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
‐QuantiFERON Gold In-Tube
•Offer several potential advantages over the tuberculin skin test (TST)
MMWR 2010;59(No.RR‐5):1‐14
Comparison of Skin Test & IGRA
Characteristic TST IGRA
Antigens studied Many -PPD ESAT-6, CFP-10, (TB-7.7)
Cross-reactivity with BCG Yes Unlikely
Cross-reactivity with NTM Yes Less Likely
Estimated sensitivity, TB in immunocompetent adults
75-90% 75-95%
Estimated specificity, TB inimmunocompetent adults
70-95% 90-100%
Distinguish between TB infection No No
Page 45
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Distinguish between TB infectionand TB disease
No No
Boosting Yes No
Patient visits required Two One
Pediatr Infect Dis J 2006;25:941
11/15/2011
24
IGRAs: Advantages
•One visit: optimal if adherence issues
•Decreased confusion about interpretation: one cut-off irrespective of age, immune status, and TB risk factors
•Enhanced specificity: optimal for BCG-immunized
Page 46
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
persons
IGRA: Limitations
•Indeterminate results: decrease the utility of a screening toolscreening tool
•One cut-off: is this appropriate across risk strata?
•Unknown dynamics of when assays become positive
•Discordance: interpretation if TST and IGRA provide different results
Page 47
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
•Limited pediatric data: especially for the most vulnerable risk groups
11/15/2011
25
Sensitivity plummets with CD4 < 200
HIV-infected Children
with CD4 < 200
Sensitivity: TSPOT > QFN > TST
Page 48
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
We don’t know the dynamics of IGRAs in HIV+ kids
No association with QFN result and CD4 (but n=14 with + TST)
Malnourished Children
•251 malnourished children, of whom 47% had helminthic infection (Ascaris, Trichuris)
•Test agreement: κ = 0.55 between TST and QuantiFERON
•25% had indeterminate test results
Page 49
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
•Degree of malnutrition and helminth infection were associated with indeterminate IGRA results
Pediatrics 2010;126:e1522
11/15/2011
26
Cancer Center Patients•34 newly diagnosed children with cancer (S. Africa)
•TST vs. T-SPOT vs. QuantiFERON
7 ere (+) ith an test (less than e pected)•7 were (+) with any test (less than expected)
•IGRAs had 12-15% indeterminate results
‐ In 1/5 of cases, TSPOT could not be completed because of low cell counts (controls failed)
•Multiple discordances:
Page 50
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
‐Between TST and both IGRAs
‐Between the IGRAs
Conclusion: no stand-alone test helpful in this population
Int J Tuberc Lung Dis 2010;14:689
Renal Patients
•Conversions and reversions of IGRAs seen
‐Conversions: 22% and 27% for QFN and T-SPOT
‐Reversions: 16% and 30% for QFN and T-SPOT
•Most studies suggest QFN is better for this group
•Indeterminate results range from 3-15%
•Results can be dramatically different if blood b i d di l i
Page 51
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
obtained pre- or post-dialysis
‐ IGRA should be done pre-dialysis
Transpl Infect Dis 2009;11:28 / J Infect 2010;61:144
11/15/2011
27
Diabetics
•Adult type II diabetics with culture-positive TB*TB
•QFN: 70% sensitive
•T-SPOT: 93% sensitive
•Seemed to perform as
Page 52
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
pwell as TST
Int J Tuberc Lung Dis 2011;15:179
* DM is single most common predisposing medical condition in TX adults with TB disease
TST preferred, IGRA acceptable
•Children < 5 years of age
IGRA preferred, TST acceptable
•BCG recipients
Page 53
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
MMWR 2010;59:RR‐5
p•Groups with historically low rates of return for TST reading
11/15/2011
28
Either IGRA or TST can be used
•Contact investigations
•Surveillance programs for healthcare workers
Page 54
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
MMWR 2010;59:RR‐5
Both TST and IGRA should be consideredI iti l IGRA i d t i t b d li•Initial IGRA indeterminate or borderline
•When initial test (TST or IGRA) is negative and:
‐There exists clinical suspicion for TB disease
‐Risk of infection, progression, and poor outcome higher
•When initial test (TST or IGRA) is positive and:
Page 55
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
•When initial test (TST or IGRA) is positive and:
‐Need additional evidence to increase compliance
‐Healthy persons with low risk for both infection and disease progression
MMWR 2010;59:RR‐5
11/15/2011
29
What to do with discordant results?
•In patients in whom disease is suspected or at high risk for progression from infection, treat if any test positivepositive
•For patients without risk factors, treat if the more specific test is positive
Page 56
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Case: A.N. (2010)
•19mo M presents with fever, altered mentation. No medical history or known contacts with TB.
Page 57
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
11/15/2011
30
Case: A.N. (2010)CSF Source
WBC RBC Protein Glucose Smear AFB Cx
EVD 15 17,315 58 35 ‐ ‐
•PPD: 0 mm
•QuantiFERON: indeterminate
•T-SPOT: ‘wicked positive’
LP 111 25 512 < 20 ‐ ‐
Page 58
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
T SPOT: wicked positive
•Mother’s (now former) boyfriend found to have pulmonary TB after contact investigation
Acid-Fast Culture Yield
Specimen Culture Yield
Sputum/gastric aspirate 30-40%
Lymphatic tissue 75%
Pleural fluid 20-40%
Cerebrospinal fluid 20-50%
Pericardial fluid 0-42%
Ascitic fluid 30%
Page 59
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Skin biopsy 20-50%
Skeletal biopsy 75%
Paed Resp Rev 2007;8:107
11/15/2011
31
So, Our Culture Yield is Horrible; Now What?
•Great contact investigations to identify source g ycases for our patients (cultures by proxy)
•Try new methods of obtaining cultures
Page 60
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
•Try new methods of obtaining cultures
Gastric Aspirates
•Inpatient procedure
•Overnight fasting•Overnight fasting
•Lavage with NS if volume < 20cc
•Generally done qAM x3
•Inpatient costs substantial
Page 61
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
•AFB smear yield: minimal
•AFB Culture yield: 20-30%
11/15/2011
32
Induced Sputum
•Outpatient procedure•2-3h fasting periodg p•Pretreated with salmeterol; nebulized saline, then CPT given
•Nasopharynx suctioned
•One specimen sufficient
Page 62
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
•Minimal costs•AFB smear yield: 50%•AFB Culture yield: 25-30%
Lancet. 2005;365:130
Page 63
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics Photo courtesy of Paul Mullan, M.D.
11/15/2011
33
TB Infection Control
•In the mid-1990s, TCH began to require that adults and adolescents accompanying inpatient children with suspected tuberculosis undergo chest radiography to rule-p g g p yout infectious pulmonary TB
•A previous report from TCH [Muñoz et al. Infect Control Hosp Epidemiol 2002;23:568-572.] demonstrated that 15% of the adults accompanying hospitalized children with suspected tuberculosis had previously undiagnosed pulmonary TB
Page 64
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
pulmonary TB
•Results from this study also showed that no healthcare worker who cared for a child with tuberculosis became infected [conversion of the TST]
Infect Control Hosp Epidemiol 2002;23:568 and 2011;32:188
When do we worry about it?
•Older adolescents
•Children with certain findings on CXR
•Producing sputum
•Any draining skin lesions
Page 65
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Infect Control Hosp Epidemiol 2011;32:188
11/15/2011
34
If we are worried, what do we do?
•N95 respirator for you
•Simple facemask (not N95) for patient
•Keep patient in room
Page 66
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
History of Drug-Resistant TB
Drug Year Introduced Year of 1st Documented Resistance
Streptomycin 1944 1948
Isoniazid 1952 1952
Pyrazinamide 1952 1964
Ethambutol 1960 1965
Page 67
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Rifampin 1966 1968
Fluoroquinolones 1988 1992
11/15/2011
35
Total drugs to treat pan-susceptible TB
Page 68
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Total drugs to treat 1 case of multidrug-resistant (MDR)* TB
Page 69
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
*MDR: resistant to at least INH and RifampinXDR (extensively drug‐resistant): MDR + resistance to fluoroquinolones + injectable agents
11/15/2011
36
DOTS (directly‐observed therapy, short‐course): administration of medications to persons with TB disease by dispassionate 3rd partySt d d f f TB di•Standard of care for TB disease in the United States
•Provided free of charge to patient•Removes some barriers to care•Increases adherence, thereby
Page 70
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Photos courtesy of Manish Shah, MD
decreasing risk of selecting out for drug‐resistant organisms by sporadic medication usage
Treatment
TB•TB exposure
•TB infection
•TB disease
Page 71
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
11/15/2011
37
TB Exposure
•Children < 5 years of age with a negative PPD, normal CXR and examination exposed to contact with suspected TBwith suspected TB
•Provide chemoprophylaxis in the window period (8-10 weeks) pending repeat skin testing
•Children > 4 yrs of age also need sequential skin
Page 72
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Children > 4 yrs of age also need sequential skin testing, but no window chemoprophylaxis
Why Do We Do This?To Prevent This:
Page 73
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
E.Q. 2009
11/15/2011
38
Why do we treat TB infection?
•Risk of developing TB disease with untreated + PPD:
‐5-10% lifetime risk in most patients
‐40% risk in infants
‐5-10% annual risk in HIV-infected patients
•½ of lifetime risk in 1st 1-2 yrs after PPD conversion
•Remainder of risk evenly spread over lifetime
Page 74
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Remainder of risk evenly spread over lifetime
•We can reduce risk by 90-95% with INH
Red Book Statement on TB Infection
•“All infants, children, and adolescents who have a positive PPD result but no evidence of TB disease and who have never received antituberculosis therapy should be considered for INH unless resistance to INH is suspected or a specific contraindication exists”
Page 75
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Red Book 2009, p691
11/15/2011
39
How is LTBI different in children?
•Risk of disease progression
•Identifying time of infection
•Identification of source case
•Medication tolerance
Page 76
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Medication tolerance
Risk of Progression to Disease, Stratified by Patient Age
Page 77
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Pediatrics in Review 2010;31:13NEJM 2011;364:15
Risk of disease progression in adults: 1‐13% lifetime risk
11/15/2011
40
Pinpointing time of infection
•Most young children are by definition ‘new’ converters
•So, this is best opportunity to prevent future disease:
‐½ of lifetime risk is in first 1-2 years after TST conversion
‐Risk substantively higher for infants
Page 78
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Page 79
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
•Children have circumscribed social networks•Often the person who infected the child is a caregiver/relative•Easier to identify source case, and child is unlikely to have > 1 source case
NEJM 2011;364:730
11/15/2011
41
Medication Tolerance•Pediatrics:
‐5% risk of side effects in children•Most minor – abdominal pain without elevation in LFTs
‐3 3% risk of elevated LFTs in 1970s with INH+RIF‐3.3% risk of elevated LFTs in 1970s with INH+RIF
•Adults:
Page 80
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
Pediatrics 2006;117:e148; Pediatrics 1983;72:491
NEJM 2011;364:15IJTLD 2010;14:1374
•Take home messages:
‐educate families on side effects
Page 81
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
‐ low threshold for checking LFTs if symptomatic
‐screen for LTBI judiciously
Pediatrics 2008;121:e1732
11/15/2011
42
Page 82
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics Chest 2010;137:737
TB Prevention
•Isoniazid (INH) = mainstay of therapy
‐10-15 mg/kg single daily dose if given by family
‐20-30 mg/kg twice weekly if given by health department
‐Duration: 9 months
•Alternative: rifampin x 6 months
‐ If person around child with TB is known to have INH-resistant
Page 83
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
pdisease or if child is INH-intolerant
11/15/2011
43
LTBI Treatment Pearls•Use INH suspension only in children < 5 kg
‐Otherwise, give tablets that can be crushed & mixed with food
•Compliance with 9 months of INH averages a bit over 50%; p g ;be skeptical
•Use health department to administer medications to high-risk patients: infants, immunocompromised children, recent contacts
•When children aren’t tolerating INH, the problem is more often with the parent than the child
Page 84
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
p
•Routine LFTs not indicated unless: concomitant administration of other hepatotoxic drugs; pre-existing liver disease; or signs/symptoms of hepatitis
Therapy for TB Disease•Start 4-drug therapy (a change from 2006 Red Book)
‐INH, rifampin (RIF), pyrazinamide (PZA), and ethambutol (EMB); INH/RIF are the backbone of therapy
•Use PZA only during 1st 2 months for susceptible TB
‐This is your ‘shortening agent’: consolidate from 9 to 6 months of therapy
•Stop EMB once culture results known, if have pan-susceptible TB
‐This is your insurance in case you have drug-resistant TB
Page 85
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
•Anticipate minimum 6 month therapy, and we often extend it to longer periods, especially for extrapulmonary disease
•Always administered by directly observed therapy (DOT)
2009 Red Book
11/15/2011
44
Notes on TB DrugsDrug Side Effects Other notes
INH Peripheral neuropathy; seizures in B6 helps prevent neuropathy and is p p yoverdose
p p p yonly treatment for INH seizures, but doesn’t prevent hepatotoxicity
RIF Orange discoloration of secretions; inactivates oral contraceptives; many drug interactions
Please warn of Longhorn‐orange urine!
PZA Can increase uric acid gout symptoms; rash
Of 1st‐line drugs, greatest association with hepatotoxicity
Page 86
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
EMB Optic neuritis, red‐green color blindness
Despite side effects, has very poor CNS penetrance and not used for meningitis
*All primarily hepatically metabolized, except EMB, which is also renally excreted
Peds in Review 2010;31:13
Conclusions
•Screen all children for TB risk factors via questionnaire•Traditional culture techniques are of much lower yield in
hild d ith d ltchildren as compared with adults•Newer diagnostic assays have recently become available, but are not without their own limitations
•IGRAs offer improved specificity, not sensitivity, compared to PPDs
•There is no substitute for a comprehensive history to elicit TB risk factors
Page 87
xxx00.#####.ppt 11/15/2011 1:02:20 PMPediatrics
TB risk factors•It is impossible to effectively manage childhood TB without close cooperation with an effective public health infrastructure